Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity
Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 Percent Company will Continue to Drive Trudhesa Growth Via 90 Field-Based Sales Representatives and Other Commercial Efforts Trudhesa Growth Momentum Continues, with 58 Percent Increase in New Prescriptions from Q2 2022 to Q4 2022 Following Expansion of Sales Force SEATTLE, Feb. 22, 2023 (GLOBE NEWSWIRE) — […]
Harmony Biosciences reports fourth quarter and full year 2022 financial results and business updates
WAKIX® (pitolisant) Net Revenue Increased ~41% Year-over-Year to $128.3 Million for Fourth Quarter 2022; ~43% to $437.9 Million for Full Year 2022 Achieved Net Income of $181.5 Million for Full Year 2022 Average Number of Patients on WAKIX Increased to ~4,900 Continued Strong Momentum in Phase 3 Idiopathic Hypersomnia (“IH”) INTUNE Study Conference Call and […]
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to 8 new employees with a grant date of February 1, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan […]
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
SYFOVRE slowed GA progression with increasing effects over time A Media Snippet accompanying this announcement is available by clicking on the image or link below: WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and Drug Administration (FDA) […]
ImmPACT Bio Appoints Biren Amin, M.B.A. to its Board of Directors
Seasoned executive brings decades of experience in capital markets, finance, and corporate strategy WEST HILLS, Calif., February 8, 2023 — ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced the appointment of Biren Amin, M.B.A., to its board of directors. Mr. […]
ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma
Phase 1/2 clinical trial expected to launch in early 2023 and will evaluate safety and preliminary impact on disease activity of IMPT-314 WEST HILLS, Calif., January 24, 2023 — ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced clearance of its […]
Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101
AB-101 is a cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers Granted Fast Track designation by U.S. FDA for the treatment of relapsed/refractory non-Hodgkin lymphoma of B cell origin, in combination with rituximab.
Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer
BURLINGAME, Calif. – (BUSINESS WIRE) – January 19, 2023 – Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the appointment of Kevin N. Heller, M.D., as chief medical officer.
Ventyx Biosciences announces pipeline updates and highlights strategic priorities at investor R&D day
Phase 2 clinical trials of VTX958 (TYK2 inhibitor) in plaque psoriasis, Crohn’s disease and psoriatic arthritis are ongoing with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis is on track to complete enrollment by mid-2023; new pharmacodynamic data support best-in-class potential […]
NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes
– NorthSea Therapeutics now has three phase II clinical stage assets in development based on its SEFA platform – Top line results of Phase 2b ICONA trial with lead programme icosabutate for NASH expected in Q1 2023 – Phase 1 trial with SEFA-1024 (being developed for the treatment of severe hypertriglyceridemia) completed in Q4 2022 […]
